Provectus News Provectus Biopharmaceuticals' P
Post# of 22757
Posted On: 09/24/2014 8:20:48 AM
Provectus News
Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress
Poster Presentation Scheduled for Sunday, September 28, 2014, From 12:45 To 1:45 pm
ESMO 2014 Congress in Madrid, Spain, Runs from September 26-30, 2014
Wednesday September 24, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at
https://www.webges.com/cslide/library/esmo/br...t#9faD03sJ.
The ESMO 2014 Congress in Madrid, Spain, runs from September 26-30, 2014. This poster presentation will be held on Sunday, September 28, 2014, beginning at 12:45 pm local time, presented by Sanjiv S. Agarwala, MD, of St. Luke's Hospital and Health Network, Bethlehem, PA.
Dr. Craig Dees, PhD, CEO of Provectus, said, "We are very pleased that these subgroup data will be presented at ESMO this year, and we are glad that our principal investigator Dr. Agarwala will be available to discuss this work with attendees."
PV-10, a 10% solution of Rose Bengal that is currently being investigated as a potential cancer therapeutic, is designed for injection into solid tumors (intralesional administration).
The complete press release is available at www.pvct.com/pressrelease.html?article=20140924 on the Provectus website.
Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress
Poster Presentation Scheduled for Sunday, September 28, 2014, From 12:45 To 1:45 pm
ESMO 2014 Congress in Madrid, Spain, Runs from September 26-30, 2014
Wednesday September 24, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at https://www.webges.com/cslide/library/esmo/br...t#9faD03sJ.
The ESMO 2014 Congress in Madrid, Spain, runs from September 26-30, 2014. This poster presentation will be held on Sunday, September 28, 2014, beginning at 12:45 pm local time, presented by Sanjiv S. Agarwala, MD, of St. Luke's Hospital and Health Network, Bethlehem, PA.
Dr. Craig Dees, PhD, CEO of Provectus, said, "We are very pleased that these subgroup data will be presented at ESMO this year, and we are glad that our principal investigator Dr. Agarwala will be available to discuss this work with attendees."
PV-10, a 10% solution of Rose Bengal that is currently being investigated as a potential cancer therapeutic, is designed for injection into solid tumors (intralesional administration).
The complete press release is available at www.pvct.com/pressrelease.html?article=20140924 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼